



DISCOVERIES FOR HEALTHIER LIVES

PROTECTING ADOLESCENTS AND YOUNG ADULTS FROM MENINGITIS B



“Meningococcal meningitis B is a devastating disease, which, though rare, significantly impacts affected individuals and families. Vaccines have been available and recommended since 2005 to help protect against four other serogroups of meningococcal disease, and we hope that Trumenba will become a recommended vaccine in routine adolescent immunization programs to help prevent meningococcal B disease.”

FRANKIE MILLEY

FOUNDER/NATIONAL EXECUTIVE DIRECTOR
MENINGITIS ANGELS

and mother to an only child who died from meningitis

TRUMENBA® APPROVED AND AVAILABLE TO PREVENT MENINGITIS B

Trumenba (meningococcal group B vaccine) is the first FDA-approved vaccine for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B in individuals 10 through 25 years of age. Trumenba was reviewed and approved under the FDA’s Breakthrough Therapy designation and Priority Review programs.

The unmet medical need was great. This disease is characterized by high fatality rates and rapid onset, often within 24 hours. For individuals 11–24 years of age, approximately 30 percent of meningococcal disease is serogroup B in the U.S., and 10 percent of these cases result in death.¹ As many as 60 percent of adolescent survivors of meningococcal disease, 15–19 years of age, suffer from permanent life-altering consequences such as hearing loss, neurologic damage, or loss of a limb.² Between the years 2010 and 2012, the estimated average number of annual serogroup B cases in 11- through 24-year-olds was 48–56 cases in the U.S.³

- 1 Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2013 March 22; 62(RR02); 1–28. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm>. Last updated March 22, 2013. Accessed November 17, 2014.
- 2 Borg J, Christie D, Coen PG, Pooy R, Viner RM. Outcomes of Meningococcal Disease in Adolescence: prospective, matched-cohort study. *Pediatrics*. 2009; 123: e502–e509.
- 3 MacNeil J. Epidemiology of Serogroup B Meningococcal Disease, United States. Advisory Committee on Immunization Practices, October 30, 2014. <http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-10/mening-02-MacNeil.pdf>.